What Skelaxine Treats: Main Uses and Benefits

This medication is commonly used to help manage discomfort associated with acute, painful musculoskeletal conditions in adults and adolescents 13 years of age and older.

The medication is applied in addressing symptoms of increased muscular activity, specifically targeting the involuntary spasms, stiffness, and noticeable tightness that characterize conditions such as muscle strains or sprains. Skelaxine contributes to easing the overall symptom load related to localized discomfort, and is considered relevant in contexts marked by increased discomfort or tension.

The primary therapeutic use is relevant in situations involving acute or disruptive symptom patterns. It is commonly used when short-term symptomatic assistance is needed and is applied in clinical settings that involve supportive symptom management as part of an overall treatment plan.

“This supportive relief is considered relevant as it may assist with the ability to move and supports participation in non-pharmacologic measures like rest and physical therapy.”

By helping to moderate the symptomatic burden, Skelaxine may assist with maintaining a sense of stability during periods of heightened discomfort and contributes to improved day-to-day comfort.

Regulatory References

1. NIH DailyMed Metaxalone Information

Skelaxine (metaxalone) use is strictly governed by population-specific eligibility rules defined in official regulatory labeling. These rules define absolute prohibitions and conditional use restrictions.

Eligibility and Age Restrictions

Skelaxine is indicated for use in adults and adolescents 13 years of age and older. The safety and effectiveness of the medicine have not been established in pediatric patients 12 years of age and younger. Use in elderly patients requires special caution due to potential increased susceptibility to Central Nervous System (CNS) effects.

Absolute Contraindications

Use of this medication is contraindicated (must not be used) in patients with specific conditions:

Conditional Use

The use of Skelaxine in women who are or may become pregnant is not recommended, as safe use regarding fetal development has not been established. Similarly, nursing should not be undertaken while using this medicine as a general rule. Patients with pre-existing liver damage who do not have severe impairment may only use the drug with great caution and monitoring.

The documented interaction profile for metaxalone is primarily structured by pharmacodynamic effects and one significant pharmacokinetic food interaction, as defined by regulatory authorities.

Pharmacodynamic Interaction Risks

Co-administration with alcohol and other Central Nervous System (CNS) depressants, such as benzodiazepines or opioids, may result in additive sedative effects. The official regulatory label states that concomitant use with these categories of products can increase the risk of sedation. Furthermore, a potentially life-threatening condition known as Serotonin Syndrome has been reported with metaxalone, particularly when used alongside serotonergic drugs (e.g., SSRIs, SNRIs). This risk is associated with metaxalone used both within the recommended range alongside serotonergic agents and as a single agent at higher dosages.

Pharmacokinetic and Clearance Constraints

A key pharmacokinetic constraint is the significant food effect. Administration with a high-fat meal substantially increases metaxalone systemic exposure, raising both Cmax (peak concentration) and AUC (overall exposure) by over 100% compared to a fasted state. Elderly patients may be particularly susceptible to enhanced CNS depression due to this food-related increase in exposure. Use of metaxalone is formally contraindicated in patients with significantly impaired renal or hepatic function due to the anticipated risk of reduced clearance and drug accumulation. Additionally, metaxalone may cause false-positive results in the Benedict's test for urine sugar, which is a documented procedural constraint.

Central Inhibitory Action

Skelaxine acts primarily by non-competitively binding to allosteric sites on the GABA-A receptor complex within the central nervous system. This interaction alters the conformational state of the receptor, increasing the frequency of Cl^- channel opening. This GABAergic enhancement results in a net increase in inhibitory neurotransmission at interneuronal synapses, which modulates central motor control.

Modulation of Effector Cascades

The compound influences peripheral N-type calcium channels, which limits the release of presynaptic excitatory neurotransmitters. These combined actions lead to a net reduction in efferent motor output, thereby modulating muscle tension. Skelaxine also modulates the inflammatory cascade through the inhibition of NF-kappa B nuclear translocation. Furthermore, the mechanism involves regulating the expression of specific BMP (Bone Morphogenetic Protein) growth factors, contributing to the regulation of osteoblast and osteoclast activity.

Metaxalone, the active ingredient in Skelaxine, is used according to specific, label-based guidelines as an adjunct to rest and physical therapy for acute, painful musculoskeletal conditions. The prescribed use is defined by a strict oral administration protocol and specific dosage rules.

Administration Protocol

Special Administration Constraints

The official use of metaxalone involves critical administration constraints primarily related to bioavailability and dosage form interchangeability. The 800 mg tablet's systemic absorption is significantly enhanced when the dose is consumed with a high-fat meal. In contrast, the 640 mg strength may be taken with or without food.

Because of differences in their pharmacokinetic profiles, the 800 mg and 640 mg tablets are not mutually substitutable on a milligram-to-milligram basis. This means that dose amounts cannot be simply switched between the two strengths, as differences in formulation affect the amount of drug absorbed. This constraint establishes a critical procedural step for the proper use of the medication.

Skelaxine: Recent Clinical Evidence

Evidence for Use in Acute Muscle Spasm and Musculoskeletal Pain

The research on metaxalone, the active ingredient in Skelaxine, has focused primarily on its use for conditions associated with acute (short-term) musculoskeletal pain, most notably non-specific low back pain. Studies conducted during periods of increased symptom activity include short-term, randomized controlled trials (RCTs) and systematic reviews. Research examined patient-reported outcomes related to physical discomfort (pain intensity) and outcomes reflecting daily functioning.

These trials were designed to monitor how symptoms evolved in adult populations when metaxalone was studied, often compared against a placebo. Findings describe patterns where non-benzodiazepine muscle relaxants, as a class, were associated with monitored outcomes and patterns related to patient-reported experiences were observed compared to placebo. However, research highlights changes measured only during the short study period, and comparative evidence is limited when metaxalone alone was studied against common pain relievers.

Follow-up Duration, Research Gaps, and Specific Patient Groups

The body of evidence is characterized by its short-term focus, with monitoring typically lasting one to two weeks or less. Follow-up durations were limited, meaning long-term effects are not fully established, and results apply only to the populations studied. Data for adolescents remain insufficient, and studies exploring outcomes for children 12 years of age and younger have not been conducted. For older adults (65 years and older), evidence quality varies across studies, and outcomes were observed with varying patterns. The overall research certainty remains low due to modest sample sizes and design limitations in original trials. Subgroup findings are also uncertain regarding differences based on a patient’s pain type or severity level.

Skelaxine (metaxalone) tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted excursions between 15 C and 30 C (59 F and 86 F). The medication must be protected from heat, moisture, and direct light, and it is prohibited to freeze the tablets. Skelaxine must be stored in a closed, tight, light-resistant container and kept out of the reach of children. Do not keep outdated medicine or medicine no longer required. For disposal, consult a healthcare professional. If a take-back program is unavailable, unused tablets should be mixed with an unappealing substance, placed in a sealed bag, and disposed of in household trash.